##  [Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease](/us-en/news/media-releases/novartis-kisqali-shows-overall-survival-benefit-hrher2-advanced-breast-cancer-consistent-findings-patients-more-aggressive-disease-0 "Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease") 

  May 27, 2020